SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.

Several polymorphisms in the 5alpha-reductase type 2 (SRD5A2) gene have been implicated as risk factors for prostate cancer. We performed a meta-analysis of 9 studies (12 comparisons) with V89L genotyping (2558 prostate cancer cases and 3349 controls), 7 studies (8 comparisons) with A49T genotyping (1594 cases and 2137 controls), and 4 studies with TA repeat genotyping (1109 cases and 1378 controls). The random effects odds ratio (OR) for the L versus V allele was 1.02 [95% confidence interval (CI), 0.94-1.11]. There was no suggestion of an overall effect either in recessive or dominant modeling, and comparison of L/L versus V/V also showed no differential prostate cancer susceptibility (OR, 1.03; 95% CI, 0.83-1.28). The random effects OR for the T versus A allele was 1.56 (95% CI, 0.93-2.62). However, excluding the first published study there was no evidence for any effect (OR, 1.08; 95% CI, 0.72-1.61). Moreover, the T allele had a low prevalence (0%, 1%, and 2% in Asian, African and European controls, respectively). The random effects OR for longer versus short TA alleles was 0.88 (95% CI, 0.74-1.05). Longer TA allele homozygotes were nonsignificantly under-represented among prostate cancer cases (OR, 0.53; 95% CI, 0.26-1.06). We exclude a role for the V89L polymorphism in conferring susceptibility to prostate cancer. The A49T and TA repeat polymorphisms may have a modest effect on prostate cancer susceptibility, but bias and chance findings cannot be excluded; any genuine genetic effects would account only for a small proportion of prostate cancer in the population.

[1]  John P A Ioannidis,et al.  Genetic associations: false or true? , 2003, Trends in molecular medicine.

[2]  Thomas A Trikalinos,et al.  Genetic associations in large versus small studies: an empirical assessment , 2003, The Lancet.

[3]  J. Ioannidis,et al.  Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  O. Cussenot,et al.  Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate. , 2002, European journal of endocrinology.

[5]  J. Brooks,et al.  Polymorphisms in the androgen receptor and type II 5α‐reductase genes and prostate cancer prognosis , 2002, The Prostate.

[6]  M. Marberger,et al.  Association of polymorphisms within androgen receptor, 5α‐reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men , 2002, The Prostate.

[7]  J. Johansson,et al.  5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. , 2002, Pharmacogenetics.

[8]  M. Pike,et al.  Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  M. Marberger,et al.  Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. , 2002, The Prostate.

[10]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[11]  F. Mostofi,et al.  Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  T. Stamey,et al.  Genetic polymorphisms in the androgen receptor and type II 5 alpha-reductase genes in prostate enlargement. , 2001, The Journal of urology.

[13]  O. Cussenot,et al.  Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways , 2001, Cancer.

[14]  T. Katoh,et al.  Impact of genetic polymorphisms of 17‐hydroxylase cytochrome P‐450 (CYP17) and steroid 5α‐reductase type II (SRD5A2) genes on prostate‐cancer risk among the Japanese population , 2001, International journal of cancer.

[15]  J. Schleutker,et al.  A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland , 2001, British Journal of Cancer.

[16]  M. Forrest,et al.  The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  J. Ioannidis,et al.  Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Trachtenberg,et al.  V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. , 2001, Urology.

[19]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[20]  J. Stanford,et al.  Familial prostate cancer. , 2001, Epidemiologic reviews.

[21]  A. Hsing.  Hormones and prostate cancer: what's next? , 2001, Epidemiologic reviews.

[22]  N. Makridakis,et al.  Molecular epidemiology of hormone-metabolic loci in prostate cancer. , 2001, Epidemiologic reviews.

[23]  C. Franceschi,et al.  Evidence for an Association between the SRD5A2 (Type II Steroid 5α-Reductase) Locus and Prostate Cancer in Italian Patients , 2002, Disease markers.

[24]  J. Stanford,et al.  Genetics of prostate cancer: too many loci, too few genes. , 2000, American journal of human genetics.

[25]  T. Rebbeck,et al.  Association of SRD5A2 genotype and pathological characteristics of prostate tumors. , 2000, Cancer research.

[26]  P. Febbo,et al.  The V89L Polymorphism in the 5α-Reductase Type 2 Gene and Risk of Prostate Cancer , 1999 .

[27]  M. Pike,et al.  Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA , 1999, The Lancet.

[28]  Jack A. Taylor,et al.  Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). , 1999, Carcinogenesis.

[29]  J. Ioannidis,et al.  Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data. , 1999, Journal of clinical epidemiology.

[30]  G. Miller,et al.  Molecular genetics and epidemiology of prostate carcinoma. , 1999, Endocrine reviews.

[31]  J. Ioannidis,et al.  Quantitative Synthesis in Systematic Reviews , 1997, Annals of Internal Medicine.

[32]  L. Vatten,et al.  Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  M. Pike,et al.  A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. , 1997, Cancer research.

[34]  M. Stampfer,et al.  Prospective study of sex hormone levels and risk of prostate cancer. , 1996, Journal of the National Cancer Institute.

[35]  A. Whittemore,et al.  Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  M. Pike,et al.  Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. , 1995, Cancer research.

[37]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[38]  D. Russell,et al.  Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. , 1993, The Journal of clinical investigation.

[39]  D. Russell,et al.  Unusual length polymorphism in human steroid 5α-reductase type 2 gene (SRD5A2) , 1993 .

[40]  U. Francke,et al.  Molecular genetics of steroid 5 alpha-reductase 2 deficiency. , 1992, The Journal of clinical investigation.

[41]  T C Chalmers,et al.  Cumulative meta-analysis of therapeutic trials for myocardial infarction. , 1992, The New England journal of medicine.

[42]  M. Pike,et al.  5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males , 1992, The Lancet.

[43]  J. Wilson,et al.  Characterization of the cytosol androgen receptor of the human prostate. , 1983, The Journal of clinical endocrinology and metabolism.